Nicotinic Agonist Action
Nicotinic Agonist Action - Related Videos
01:28
Adrenergic Agonists: Mixed-Action Agents
0 Views •
2023
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response. Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
00:59
Direct-Acting Cholinergic Agonists: Pharmacological Actions
0 Views •
2023
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
01:18
Indirect-Acting Cholinergic Agonists: Mechanism of Action
0 Views •
2023
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme. Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:30
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
0 Views •
2023
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain. At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
08:47
Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration
0 Views •
Cited by 12 •
2012
We have developed a novel technique of quantifying nicotinic acetylcholine receptor changes within subcellular regions of specific subtypes of CNS neurons to better understand the mechanisms of nicotine addiction by using a combination of approaches including fluorescent protein tagging of the receptor using the knock-in approach and spectral confocal imaging.
FAQs
The important sequence is receptor engagement followed by opening of the ligand-gated channel. Cation movement, particularly involving sodium and potassium, changes the membrane state and produces depolarization. That electrical shift links molecular receptor activation to downstream neuronal signaling or skeletal-muscle contraction, making channel opening the central step between agonist exposure and a rapid physiological response.
Prolonged exposure can produce receptor desensitization, a state in which continued agonist presence no longer supports the same level of receptor responsiveness. Consequently, an initial stimulatory effect may not persist unchanged over time. Accounting for this transition is important when interpreting repeated or sustained exposure and when considering how agonists influence signaling, muscle activity, or toxicity.
They can be examined according to how their interactions with nicotinic receptors relate to resulting neuronal, autonomic, or neuromuscular effects. Endogenous acetylcholine provides the physiological reference, whereas nicotine and therapeutic agents help reveal how receptor-targeting compounds alter signaling. Comparing these contexts supports pharmacological analysis without treating every agonist exposure as having identical consequences.
The nervous system and skeletal muscle provide the principal contexts because receptor activation can affect neuronal communication or neuromuscular transmission. Studies may also examine autonomic function, cognition, dependence, and toxicity as broader outcomes linked to nicotinic receptor activity. Considering these systems together helps connect receptor-level events with distinct physiological and pharmacological effects.
Pharmacological investigations can relate receptor activation to membrane depolarization, neuronal signaling, and muscle contraction, then evaluate broader consequences such as changes in cognition or autonomic function. Continued exposure may additionally be considered in relation to desensitization. This range of outcomes helps researchers characterize both immediate receptor effects and wider biological responses to nicotinic agonists.
Understanding these actions shows how compounds that influence nicotinic receptors may affect communication in neurons or at skeletal muscle. That information supports development of agents directed at these receptors while also clarifying possible outcomes involving dependence and toxicity. The same pharmacological framework therefore connects therapeutic investigation with evaluation of unwanted or harmful effects.